[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"total-neoadjuvant-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:total-neoadjuvant-treatment":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,85,110,138],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100574403",false,"NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.","ALL","18 Years",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[26,27,28,29,30,31,32,33,34,35,36],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Radiotherapy","Chemotherapy","Organ Preservation","Radiotherapy Side Effect","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[38,27,39,29,30,34,31,32,40,41,42,43,35],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","RECRUITING","2026-05-06",{"date":47,"type":48},"2026-05-11","ACTUAL",{"date":50,"type":48},"2025-01-06",{"date":52,"type":19},"2029-12-27",{"name":54,"class":55},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","OTHER",1,{"id":58,"slug":4,"hasResults":10,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":10,"sex":15,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":56},"100636301","NCT07563907","Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer","Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial","OPTION","Inclusion Criteria:\n\n* Histologically confirmed rectall adenocarcinoma\n* Low rectal cancer (AV \\\u003C 15cm)\n* cT2N0 disease, or pathologic stage T1N0 disease after endoscopic resection with at least one high-risk feature, including: Positive resection margin Lymphovascular invasion Tumor budding ≥5\n* Ability to understand and comply with the requirements of the clinical trial\n\nExclusion Criteria:\n\n* Patients who prefer radical rectal resection\n* Prior history of surgery for rectal cancer\n* Recurrent rectal cancer\n* Synchronous metastatic rectal cancer\n* Evidence of lymph node metastasis or distant metastasis on abdominopelvic CT or chest CT, including para-aortic, common iliac, or external iliac lymph node metastasis\n* Uncontrolled active infection or other uncontrolled medical condition\n* Known hypersensitivity to chemotherapy\n* Patients considered unsuitable for participation in the clinical trial by the principal investigator or study personnel","19 Years","79 Years",{"count":67,"type":19},292,[69],"NA","Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized Trial\n\nThe goal of this clinical trial is to find out if adding consolidation chemotherapy with capecitabine after total neoadjuvant chemoradiotherapy (TNT) works to improve oncologic outcomes in patients with stage I rectal cancer. It will also comparethe safety of adding consolidation chemotherapy before local excision.\n\nThe main questions it aims to answer are:\n\n* Does adding consolidation chemotherapy increase the rate of pathologic complete response?\n* What medical problems or side effects do participants have during and after treatment?\n\nResearchers will compare TNT followed by local excision to TNT followed by consolidation chemotherapy with capecitabine and then local excision to see if adding consolidation chemotherapy improves tumor response and treatment outcomes.\n\nParticipants will:\n\n* Receive TNT for stage I rectal cancer\n* Be randomly assigned to one of two treatment groups\n* Undergo local excision after preoperative treatment\n* Visit the clinic for checkups and tests to evaluate tumor response, side effects, recurrence, survival, quality of life, bowel function, urinary function, sexual function, circulating tumor DNA, and treatment-related costs",[31,72,27,73,74],"Rectal Cancer Stage I","Consolidation Therapy","Capecitabine","NOT_YET_RECRUITING","2026-04-26",{"date":78,"type":48},"2026-05-04",{"date":80,"type":19},"2026-06-01",{"date":82,"type":19},"2035-12-31",{"name":84,"class":55},"Seoul National University Hospital",{"id":86,"slug":4,"hasResults":10,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":56},"100574828","NCT06764355","Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","Total Neoadjuvant Therapy With Induction Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma","NICE-ESCC","Inclusion Criteria:\n\n1. Pathologically proven squamous cell carcinoma of the intrathoracic esophagus.\n2. Locally advanced disease, which is defined by the TNM system of the American Joint Committee on Cancer (AJCC) Cancer Staging System (8th edition), fulfilling one of the following criteria as determined by staging procedures (including but not limited to endoscopic ultrasound, computed tomography, bronchoscopy or positron emission tomography):\n\n   1. cT3\u002F4a, N0, M0;\n   2. cT1-4a, N1-3, M0.\n3. Tumor length longitudinal ≤ 10cm and radial ≤ 5cm.\n4. The tumor must not extend more than 2cm into the stomach.\n5. No invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.\n6. Age ≥ 18 and ≤ 75 years old.\n7. Performance status ECOG 0\\~1.\n8. Adequate bone marrow reserves, defined as:\n\n   1. white blood cells (WBC) ≥ 3,000\u002Fµl or neutrophil count (ANC) ≥ 1,500\u002Fµl;\n   2. platelets ≥ 100,000\u002Fµl.\n9. Adequate liver function reserves, defined as:\n\n   1. hepatic transaminases ≤ 2.5 x upper limit of normal (ULN);\n   2. serum total bilirubin ≤ 2.0 x upper limit of normal (ULN).\n10. Adequate renal function: Creatinine ≤1.5 x upper normal limit or estimated creatinine clearance ≥ 50 ml\u002Fmin (estimated by Cockcroft-Gault formulation)\n11. Written informed consent.\n12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be mandatory.\n13. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section - Contraception, for the course of the study through 120 days after the last dose of study medication.\n\n    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n14. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n1. Adenocarcinoma\n2. Previous thoracic irradiation\n3. Previous systemic chemotherapy\n4. Has received prior therapy with an anti-PD-1 or anti-PD-L1\n5. Synchronous diagnosis of squamous cell carcinoma in the aerodigestive tract, other than esophageal cancer.\n6. Prior malignancy, except for the following:\n\n   1. adequately treated basal cell or squamous cell skin cancer;\n   2. in-situ cervical cancer;\n   3. a \"cured\" malignancy more than 5 years prior to enrollment.\n7. Significant co-morbid disease, which prohibits the conduction of immunochemotherapy, concurrent CRT, or radical surgery, such as active systemic infection, symptomatic cardiac or pulmonary disease, or psychiatric disorders.\n8. Documented myocardial infarction within the 6 months preceding registration (pretreatment ECG evidence of infarct only will not exclude patients). Patients with a history of significant ventricular arrhythmia requiring medication. Patients with a history of 2nd or 3rd degree heart block.\n9. Pre-existing motor or sensory neurotoxicity greater than grade 1.\n10. Patients with prior allergic reactions to drug containing Cremophor, such as teniposide or cyclosporine.\n11. Weight loss \\> 15%.\n12. Dementia or altered mental status that would prohibit the understanding and completion of informed consent.\n13. Estimated life expectancy less than 3 months.\n14. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n15. Has a known history of active TB (Bacillus Tuberculosis)\n16. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n17. Has known history of, or any evidence of active, non-infectious pneumonitis, interstitial lung disease or pulmonary fibrosis.\n18. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n19. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n20. Patients with untreated chronic HBV or chronic HBV carriers whose HBV DNA is ≥500 IU\u002FmL, or patients with active HCV. Patients who are inactive carriers or with treated and stable hepatitis B (detectable B surface antigen and HBV DNA \\\u003C500 IU\u002FmL); patients with non-reactive HCV can be enrolled. Patients with chronic HBV infection need to be treated with anti-HBV agents while receiving immunochemotherapy and chemoradiotherapy according to the local and institutional guidelines.\n21. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines are live attenuated vaccines, and are not allowed.\n22. Has received organ transplantation.\n23. Has declined esophagectomy.","75 Years",{"count":94,"type":19},50,[22],"Effective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer. A more effective systemic therapy with anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) plus cisplatin-based doublet chemotherapy, which has shown with high tumor response rate and improved survivals in patients with late-stage ESCC, may provide crucial benefit to patients with locally advanced disease by improving the systemic control, downstaging the locoregional tumor burden and reducing recurrence and metastasis.\n\nCollectively, the investigators hypothesize that total neoadjuvant therapy (TNT) approach-consisting of induction immunochemotherapy followed by CRT-is a promising strategy to enhance the outcomes for participants with locally advanced esophageal squamous cell carcinoma.",[98,27,99],"ESCC","Pathological Complete Response",[98],"2026-01-25",{"date":103,"type":48},"2026-01-27",{"date":105,"type":48},"2025-07-23",{"date":107,"type":19},"2028-12",{"name":109,"class":55},"National Taiwan University Hospital",{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":92,"enrollmentInfo":116,"targetDuration":4,"studyType":20,"phases":118,"briefSummary":119,"conditions":120,"keywords":127,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":56},"100608177","NCT07198165","SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy.\n* Exclusion of patients with BRAF mutations or MSI-H status, as determined by pre-enrollment genetic testing including RAS, BRAF, and MSI analysis. RAS mutation status is permitted regardless.\n* Absence of severe intestinal obstruction symptoms and no evidence of distant metastasis confirmed by imaging examinations such as CT, MRI, or PET\u002FCT.\n* Confirmation as locally advanced rectal cancer by rectal MRI, meeting one or more of the following criteria: T3c-d or T4, N2, EMVI(+), MRF(+), lateral lymph node metastasis; or patients with low-lying rectal cancer (≤5 cm from the anal verge) unsuitable for sphincter-preserving surgery prior to neoadjuvant therapy.\n* Age 18 to 75 years.\n* ECOG Performance Status of 0 to 1, without severe comorbid medical conditions.\n* Adequate organ function:\n\nHematopoietic: Hemoglobin ≥90 g\u002FL, Platelets ≥80 × 10\\^9\u002FL, Absolute Neutrophil Count ≥1.5 × 10\\^9\u002FL.\n\nHepatic: ALT and AST \\\u003C 2.5 × ULN. Renal: Serum Creatinine \\\u003C 1.5 × ULN.\n\n* Provision of signed and dated written informed consent.\n\nExclusion Criteria:\n\n* Patients found to have BRAF mutations or MSI-H status.\n* Patients who have previously received chemotherapy, radiotherapy, immunotherapy, targeted therapy, or surgical resection for colorectal cancer prior to enrollment.\n* History or presence of another malignancy (except for early-stage basal cell carcinoma or carcinoma in situ of the cervix) within the past 3 years, with the disease not under control.\n* Patients who are pregnant (confirmed by serum or urine β-HCG test) or breastfeeding.\n* Patients with severe cardiac, hepatic, renal, neurological, or psychiatric diseases.\n* Patients with active infections.\n* Poor overall health status, with an ECOG performance status ≥2.\n* Patients who have undergone organ transplantation requiring immunosuppressive therapy, or those requiring long-term corticosteroid treatment for autoimmune diseases.\n* Patients with comorbid conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the completion of the study.\n* Known hypersensitivity to any of the study drugs.",{"count":117,"type":19},104,[22],"This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC). The hypothesis is that the addition of immunotherapy (PD-1 inhibitor) can significantly improve the complete response (CR) rate and enhance local control while reducing the incidence of distant metastasis. This study will compare the effects of sequential chemoradiotherapy and targeted therapy with or without immunotherapy following short-course radiotherapy, aiming to explore the optimal regimen for total neoadjuvant therapy.",[26,121,122,123,124,125,27,126,34],"Rectal Adenocarcinoma","Rectal Cancer, Radiotherapy","Rectal Cancer Patients","Immunotherapy","Total Neoadjuvant Therapy","Targeted Therapy",[38,125,124,128,34],"Targeted therapy","2025-09-27",{"date":131,"type":48},"2025-09-30",{"date":133,"type":48},"2025-09-05",{"date":135,"type":19},"2030-12-31",{"name":137,"class":55},"Ruijin Hospital",{"id":139,"slug":4,"hasResults":10,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":92,"enrollmentInfo":144,"targetDuration":4,"studyType":20,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":56},"100515946","NCT05998122","Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study","Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal High-Risk or Very High-Risk Patients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study","Inclusion Criteria:\n\n1. The patients and their families are able to understand and are willing to participate in this clinical study, and sign an informed consent form.\n2. Age: 18\\~75 years old, no gender limit;\n3. Pathologically diagnosed rectal adenocarcinoma: differentiated into Grade 1-3, that is, high, medium, and poorly differentiated tubular adenocarcinoma; classified as pMMR\u002FMSS.\n4. The initial TNM risk category (from Rectal cancer: ESMO Clinical Practice Guidelines, 2017 edition) is as follows: 1) \"Bad\": cT3c\u002Fd or very low localisation levators threatened, MRF clear; cT3c\u002Fd mid-rectum, cN1-N2 (extranodal), EMVI+, limited cT4aN0; 2) \"Advanced\": cT3 with any MRF involved, any cT4a\u002Fb, lateral node+.\n5. The lower edge of the tumor is located below the peritoneal reflex;\n6. No distant transfer;\n7. ECOG PS score 0-1 within 7 days before the first medication;\n8. Hepatitis B Surface Antigen (HBsAg) (-) and Hepatitis B Core Antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), hepatitis B virus deoxyribonucleic acid (HBV-DNA) must be less than 1000 copies\u002FmL or 200 IU\u002FmL before entering the group.\n9. HCV antibody (-)\n10. The main organ function is normal.\n11. No history of pelvic radiotherapy;\n12. No history of rectal cancer surgery or chemotherapy;\n13. Not accompanied by systemic infections requiring antibiotic treatment;\n14. Heart, lung, liver, and kidney functions can tolerate surgery;\n15. Others, based on the results of previous medical history, vital signs, physical examination or laboratory examination, the research doctor judges that you are suitable for participating in this clinical study.\n\nExclusion Criteria:\n\n1. Recurrent rectal cancer;\n2. Patients who are planning to undergo or have previously received organ or bone marrow transplantation;\n3. Myocardial infarction or poorly controlled arrhythmia (including QTc interval ≥ 450 ms for males and ≥ 470 ms for females) occurred within 6 months before the first medication (QTc interval is calculated by Fridericia formula);\n4. Existence of NYHA standard grade III to IV cardiac insufficiency or color Doppler ultrasound examination: LVEF (left ventricular ejection fraction) \\\u003C50%;\n5. Human immunodeficiency virus (HIV) infection;\n6. Suffer from active tuberculosis;\n7. Past and present patients with interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severely impaired lung function, etc., which may interfere with the detection and treatment of suspected drug-related lung toxicity;\n8. Patients with active or suspicious autoimmune disease, or with a history of that;\n9. Received treatment with live vaccines within 28 days before the first administration; except for inactivated viral vaccines for seasonal influenza;\n10. Have received other antibody\u002Fdrug treatments against immune checkpoints in the past, such as PD-1, PD-L1, CTLA4, etc.;\n11. Known to have a history of severe allergies to any monoclonal antibody or research drug excipients;\n12. In the past 5 years, patients have suffered from malignant tumors whose survival rate is significantly lower than the historical data of our rectal cancer survival rate (properly treated basal cell carcinoma, skin squamous cell carcinoma, small kidney cancer, breast cancer, and papillary thyroid carcinoma are not included here. range);\n13. The patient has had arterial embolism diseases in the past 6 months, such as angina pectoris, MI, TIA, CVA, etc.;\n14. Have received other types of anti-tumor or experimental treatments;\n15. The patient is a female during pregnancy or lactation;\n16. The patient has other diseases or abnormal mental states, which may affect the patient's participation in this study;\n17. There are patients who may increase the risk of participating in research and research medication, or other severe, acute and chronic diseases, who are not suitable for clinical research based on the judgment of the investigator.",{"count":145,"type":19},45,[22],"Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor regression advantage with a restricted safety profile contrasted with 3-cycle counterparts. Herein, we designed this study to further evaluate the short-term efficacy (such as pCR rate, R0 resection rate, etc.) and long-term survival (including DFS, OS, etc.) of 6-cycles consolidation therapy.",[149,27,150],"Locally Advanced Rectal Cancer","Anti-PD-1","2023-08-11",{"date":153,"type":48},"2023-08-18",{"date":155,"type":19},"2023-09-01",{"date":157,"type":19},"2028-12-31",{"name":159,"class":55},"The First Hospital of Jilin University",""]